SUTRO BIOPHARMA INC. - COMMON STOCK

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

10 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

13 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

01 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

10 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 سبتمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

14 سبتمبر 2024 03:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

11 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

22 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 أغسطس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

09 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 مايو 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

30 أبريل 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

02 أبريل 2024 06:18:56 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

25 مارس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

06 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

04 يناير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

14 ديسمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

11 ديسمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

04 ديسمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire